26 results about "Hcv hepatitis c virus" patented technology

A compound of the structure:or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

To provide compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject.SOLUTION: In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, an adjuvant, or a combination thereof.SELECTED DRAWING: None

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1 / E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1 / E2 heterodimers. The present disclosure provides HCV E1 / E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

The present disclosure provides immunogenic compositions comprising one or more T-cell epitope polypeptides, or a fusion polypeptide comprising two or more T-cell epitope polypeptides. The present disclosure provides a method for inducing an immune response to hepatitis C virus in an individual, the method comprising administering to the individual an immunogenic composition of the present disclosure.

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, ebola, Zika, West Nile, Dengue, and HCV.

The present invention provides an immunogenic composition comprising: one or more T cell epitope polypeptides, or a fusion polypeptide comprising two or more T cell epitope polypeptides. The present invention provides a method of inducing an immune response in an individual against hepatitis C virus, the method comprising administering to the individual an immunogenic composition of the invention.

Methods of identifying virus antigens are provided. In particular the antigens induce broadly neutralizing antibodies in Hepatitis C virus infections. Compositions for inducing an immune response are identified by the methods described herein.

The invention discloses a label-free double-gene synchronous detection system and a label-free double-gene synchronous detection method for optical fiber-assisted enzymatic recombinase amplification, the detection system adopts two sections of conical micro optical fibers with different interference characteristics as sensing substrates, and nucleic acid primer pairs targeting hepatitis B virus (HBV) and hepatitis C virus (HCV) are respectively fixed by click chemistry; spatial separation and amplification of double-target nucleic acid are realized; amplification products are enriched in situ on the surface of the optical fiber, local refractive index changes are caused, interference spectrums are modulated, through Fourier frequency domain analysis and band-pass filtering, target signals can be separated and tracked in real time, dependence of fluorescence labeling and thermal circulation is avoided, and the detection process and the system structure are remarkably simplified. The detection system has the advantages of high sensitivity, strong specificity and compact structure, is suitable for multi-target detection scenes such as virus co-screening and early diagnosis of diseases, is expected to realize portable deployment and remote distributed application in a resource limited environment, and has good clinical conversion value and popularization prospect.

The present disclosure describes methods of treating a hepatitis C virus (HCV) infection in a patient in need thereof by orally administering to the patient a therapeutically effective amount of a pharmaceutical composition, which may include one or more of compounds disclosed herein. The methods of treating the HCV infection in the patient may result in clearance of the HCV infection as measured by sustained virologic response.

The present invention relates to a phenylthiazolamine-based PI4KIIIβ / HDAC dual-target inhibitor, a preparation method thereof, a pharmaceutical composition thereof and applications, belonging to the technical field of medicine. The present invention provides a phenylthiazolamine-based PI4KIIIβ / HDAC dual-target inhibitor, which is a substituted phenylthiazolamine compound represented by general formula I, or a stereoisomer, hydrate or pharmaceutically acceptable salt thereof. The beneficial effects of the present invention are as follows: (1) It has the characteristics of effectively inhibiting the PI3K / Akt / mTOR signaling pathway of PI4KIIIβ and has excellent dual-enzyme inhibitory activity against PI4KIIIβ / HDAC; (2) It has low cost, good curative effect, low toxicity, and high yield of intermediate products during the synthesis process, reducing resource waste and thus being conducive to cost reduction; (3) It has high anti-hepatitis C virus activity and a small dosage.

Provided herein are compositions and methods that allow for controlled interaction between a target protein and a polypeptide to which a binding protein is fused. Compositions and methods utilize a target protein that binds to the hepatitis C virus protease inhibitor glaprevir to form a complex, and a Tn3 binding protein that specifically binds to the complex. The target protein is or is derived from a viral protease, such as an HCV NS3 / 4A protease.

Provided herein are compositions and methods that permit the controlled interaction of polypeptides to which a target protein and binding protein are fused. The compositions and methods make use of a target protein that binds to the hepatitis C virus protease inhibitor grazoprevir to form a complex, and a Tn3 binding protein that specifically binds the complex. The target protein is or is derived from a viral protease, such as the HCV NS3 / 4A protease.

The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C virus NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.

Broadly-neutralizing antibodies (bNAbs) associated with clearance of human hepatitis C virus (HCV) infection are provided. The bNAbs were generated against a novel mixture of full- length E2 ectodomain proteins to isolate 10,680 E2-reactive B cells from acute infection through multiple spontaneous viral clearance events.

The invention discloses a 6xj type hepatitis C virus subgenome replicon, the nucleotide sequences of which are shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, the 6xj type hepatitis C virus subgenome replicon is transfected into human liver cancer cells, and 6xj type hepatitis C virus subgenome replicon cells capable of efficiently replicating HCV RNA (Ribonucleic Acid) are obtained through screening. According to the 6xj type hepatitis C virus subgenome replicon, the sensitivity of the 6xj type hepatitis C virus subgenome replicon to velpatasvir and Sofosbuvir drugs is detected by utilizing the replicon system, the replicon is proved to be capable of being applied to hepatitis C virus drug screening, and the 6xj type hepatitis C virus subgenome replicon provides an important research tool for research in the fields of HCV drug-resistant site analysis, adaptive mutation functions, HCV pathogenesis, drug screening and the like.

Disclosed are a trimerization regulatory element, a method for constructing same, and use thereof. In addition to a protein A and a protein B that are obtained by splitting the hepatitis C virus protease NS3a, the trimerization regulatory element comprises a protein C. The trimerization of the trimerization regulatory element can be mediated by means of a targeting drug specific to the protease NS3a (grazoprevir / danoprevir). The trimerization regulatory element provided by the present invention has an excellent small-molecule-mediated trimerization effect, and a drug approved by the National Medical Products Administration is used. The protein used does not exist in the human body; therefore, the protein can result in better biological orthogonality. Moreover, the protein can be used as a clinically effective drug regulatory switch, effectively avoiding problems such as serious cytotoxicity and off-target effects.

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1 / E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1 / E2 heterodimers. The present disclosure provides HCV E1 / E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

Attenuated forms of virulent Zika virus and Hepatitis C virus are provided. Vaccine compositions comprising the attenuated virus and methods of eliciting a protective immune response in a subject by administering the vaccine compositions are also provided.

The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising HCV glycoprotein E2 from strain GT4a.ED43, and optionally, further HCV glycoproteins E2 from other strains and / or an adjuvant. The glycoprotein can be soluble glycoprotein or it can be displayed on the surface of a nanoparticle. Alternatively, it provides a composition comprising a nucleic acid encoding HCV glycoprotein E2 from strain GT4a.ED43, and, optionally, from other strains. The composition is useful as a vaccine, e.g., for prophylactic vaccination against HCV. The invention also provides a method for producing said composition as well as HCV glycoprotein E2 from strain GT2b.2b5 and a nucleic acid encoding the same.

The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1 / E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1 / E2 heterodimers. The present disclosure provides HCV E1 / E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

Broadly-neutralizing antibodies (bNAbs) associated with clearance of human hepatitis C virus (HCV) infection are provided. The bNAbs were generated against a novel mixture of full- length E2 ectodomain proteins to isolate 10,680 E2-reactive B cells from acute infection through multiple spontaneous viral clearance events.

The present invention relates to a phenylthiazolamine PI4KIIIβ / HDAC dual-target inhibitor, a preparation method therefor, a pharmaceutical composition thereof, and use thereof, and pertains to the technical field of medicines. The present invention provides a phenylthiazolamine PI4KIIIβ / HDAC dual-target inhibitor that is a substituted phenylthiazolamine compound represented by general formula I or a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof. The present invention has the following beneficial effects: (1) The inhibitor is characterized by effectively inhibiting the PI3K / Akt / mTOR signaling pathway of PI4KIIIβ and has efficient and excellent dual-enzyme inhibitory activity against PI4KIIIβ / HDAC. (2) The cost is low, the efficacy is good, and the toxicity is low. Moreover, the yield of intermediate products in the synthesis process is high, reducing the waste of resources and thus helping reduce the cost. (3) The inhibitor has relatively high anti-hepatitis C virus activity and is used in small doses.

The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3 / 4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.

Hepatitis C virus (HCV) soluble fusion immunogens (sE1E2) that are derived from engineered or redesigned HCV sE1 and sE2 polypeptides and are configured to form a native-like E1E2 interface are provided that can be used in vaccine formulations. Also provided are related vaccine compositions that exhibit the engineered sE1E2 immunogen on a self-assembled nanoparticle scaffold after cleavage to a sE1E2 protein having a native E1E2 conformation. Also provided are methods of using the immunogens and vaccine compositions in methods for preventing or treating HCV infection.